SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients

Merat, S and Poustchi, H and Sharifi, A-H and Nateghi, A and Hajiani, E and Gharavi, A and Somi,, M-H and Ghadir, M-R (2018) SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. JOURNAL OF VIRAL HEPATITIS, 25.

Full text not available from this repository.
Official URL: https://apps.webofknowledge.com/full_record.do?pro...
Item Type: Article
Uncontrolled Keywords: hepatitis C, hemodialysis patients
Subjects: WD Nutrition Disease and metabolic diseases
WI Digestive System
Depositing User: Unnamed user with email zamani.m@skums.ac.ir
Date Deposited: 18 Sep 2018 07:13
Last Modified: 20 Apr 2019 10:14
URI: http://eprints.skums.ac.ir/id/eprint/7209

Actions (login required)

View Item View Item